The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.
2020
DOI: 10.1016/j.annder.2020.09.552
|View full text |Cite
|
Sign up to set email alerts
|

BMS-986165, un inhibiteur oral sélectif de la tyrosine kinase 2, réduit le PASI absolu (Psoriasis Area and Severity Index) dans une étude de phase II sur le Psoriasis

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles